B707 PILL – IDENTIFICATION, MECHANISM OF ACTION, SIDE EFFECTS

Pill Identification & Overview

A distinct light blue, rectangular, multi-scored tablet debossed with “B 707” is generic Alprazolam 2 mg (commonly known by the brand name Xanax). It is widely referred to in clinical and colloquial settings as a “blue bar” or “blue Xanax”.

Characteristic – Specification

• Active Ingredient – Alprazolam
• Strength – 2 mg
• Drug Class – Benzodiazepine (Triazolobenzodiazepine)
• Color & Shape – Light blue, rectangular bar with rounded edges
• Imprint / Markings – Debossed with “B 707” across one side; multi-scored on the reverse
• Scoring – Multi-scored (three score lines dividing the tablet into four 0.5 mg sections)
• Distributor / Manufacturer – Breckenridge Pharmaceutical, Inc. / Centaur Pharmaceuticals
• Controlled Status – Schedule IV (C-IV) Controlled Substance (Prescription only)

Mechanism of Action (Pharmacology)

Alprazolam is a short- to intermediate-acting triazolobenzodiazepine that produces anxiolytic, sedative, hypnotic, muscle-relaxant, and anticonvulsant effects:

• Positive Allosteric Modulation of Receptors: Alprazolam binds to specific benzodiazepine binding sites located at the interface of and subunits on the receptor complex in the central nervous system (CNS).
• Enhanced Inhibitory Neurotransmission: Binding increases the affinity of the receptor for gamma-aminobutyric acid , the primary inhibitory neurotransmitter in the brain.
• Chloride Channel Hyperpolarization: This enhances the opening frequency of the receptor’s integral chloride ion channel, causing chloride ion influx into postsynaptic neurons. The resulting cellular hyperpolarization decreases neuronal excitability and suppresses overactive neural circuits responsible for panic and severe anxiety.

Indications & Dosage Guidelines

Therapeutic Indications

• Generalized Anxiety Disorder (GAD): Indicated for the acute management of excessive anxiety and tension associated with anxiety disorders.
• Panic Disorder: FDA-approved for the treatment of panic disorder, with or without agoraphobia.
• Anxiety Associated with Depressive Symptoms: Short-term relief of comorbid anxiety symptoms.

Typical Dosage Guidelines

• Anxiety Disorders:
• Standard starting dose: 0.25 mg to 0.5 mg administered orally 3 times daily (using lower-dose formulations).
• Titration: Can be adjusted at intervals of 3 to 4 days, up to a maximum recommended total daily dose of 4 mg/day in divided doses.

• Panic Disorder:
• Starting dose: 0.5 mg 3 times daily.
• Target dose: Often requires higher doses; clinical trials report an average therapeutic range of 3 mg to 6 mg/day in divided doses, with rare patients requiring up to 10 mg/day under close specialist supervision.

• 2 mg “B 707” Usage: Because 2 mg is a high single dose, the tablet is multi-scored so it can be split into halves (1 mg) or quarters (0.5 mg) to match a patient’s individualized titration schedule.
• Duration: Intended for short-term use (typically 2 to 4 weeks).

Side Effects Profile

Common Side Effects

• Significant somnolence, drowsiness, and sedation
• Ataxia, impaired coordination, and unsteady gait
• Dizziness and lightheadedness
• Cognitive blunting, anterograde amnesia, and concentration difficulties
• Slurred speech (dysarthria)
• Dry mouth and constipation

Serious Adverse Reactions

• Severe CNS & Respiratory Depression: Slowed breathing, profound lethargy, stupor, or coma.
• Paradoxical Reactions: Unprovoked agitation, aggression, irritability, rage, hallucinations, or behavioral disinhibition (more common in pediatric, elderly, and psychiatric populations).
• Severe Rebound Anxiety & Insomnia: Marked intensification of baseline symptoms following dose omission or rapid reduction.
• Hypotension & Syncope: Clinically significant drops in blood pressure.

Precautions & Drug Interactions

• CYP3A4 Inhibitors & Inducers: Alprazolam is heavily metabolized in the liver via CYP3A4 enzymes.
• Contraindicated/Caution: Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) significantly raise alprazolam plasma concentrations, dramatically increasing toxicity risk.
• Enzyme Inducers: Carbamazepine and St. John’s Wort accelerate clearance, drastically reducing drug efficacy.

• Alcohol & Other CNS Depressants: Concurrent ingestion of alcohol, other benzodiazepines, barbiturates, or sedatives creates profound, life-threatening synergistic CNS depression.
• Hepatic Impairment & Elderly Patients: Clearance is substantially reduced, heightening the risk of oversedation, confusion, and fall-related fractures. Starting doses should be reduced to 0.25 mg 2–3 times daily.
• Counterfeit Alert: The “B 707” blue bar is among the most heavily counterfeited pills on the illicit market. Illicit counterfeit versions frequently contain lethal doses of illicit synthetic opioids (such as fentanyl) or novel designer benzodiazepines. Authentic medication must only be obtained directly through licensed pharmacies.

Boxed Warnings & Critical Safety Information

FDA Black Box Warnings

• Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options.
• Abuse, Misuse, and Addiction: Alprazolam exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Assess each patient’s risk prior to prescribing and monitor regularly.
• Physical Dependence and Withdrawal Reactions: Continued use of benzodiazepines can lead to clinically significant physical dependence. Abrupt discontinuation or rapid dose reduction can precipitate life-threatening acute withdrawal reactions, including status epilepticus (seizures), delirium tremens, psychosis, severe tremors, and severe rebound anxiety.

• Discontinuation Protocol: Alprazolam should never be stopped abruptly after regular use. Discontinuation requires a gradual, medically supervised taper (e.g., decreasing the daily dose by no more than 0.5 mg every 3 days, often slower depending on the individual patient’s duration of therapy).
• Pregnancy & Lactation: Benzodiazepines cross the placenta and enter breast milk. Use during pregnancy is associated with neonatal flaccidity, respiratory depression, feeding difficulties (“floppy infant syndrome”), and neonatal drug withdrawal symptoms.